BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Findlay JM, Middleton MR, Tomlinson I. A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage. Ann Oncol. 2015;26:624-644. [PMID: 25214541 DOI: 10.1093/annonc/mdu449] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Zhao Z, Wang P, Gao Y, He J. The high expression instead of mutation of p53 is predictive of overall survival in patients with esophageal squamous-cell carcinoma: a meta-analysis. Cancer Med 2017;6:54-66. [PMID: 27882726 DOI: 10.1002/cam4.945] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
2 Olivera GG, Urtasun A, Sendra L, Aliño SF, Yáñez Y, Segura V, Gargallo P, Berlanga P, Castel V, Cañete A, Herrero MJ. Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next? Int J Mol Sci 2021;22:9815. [PMID: 34575974 DOI: 10.3390/ijms22189815] [Reference Citation Analysis]
3 Rumiato E, Boldrin E, Amadori A, Saggioro D. Predictive role of host constitutive variants in neoadjuvant therapy of esophageal cancer. Pharmacogenomics 2016;17:805-20. [PMID: 27181132 DOI: 10.2217/pgs-2016-0009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
4 Zhao Y, Yu Y, Li H, Zhang Z, Guo S, Zhu S, Guo Q, Li P, Min L, Zhang S. FAM175B promotes apoptosis by inhibiting ATF4 ubiquitination in esophageal squamous cell carcinoma. Mol Oncol 2019;13:1150-65. [PMID: 30854784 DOI: 10.1002/1878-0261.12474] [Reference Citation Analysis]
5 Chi J, Yang Q, Xie XF, Yang XZ, Zhang MY, Wang HY, Xu GL. Clinical significance and prognostic value of TRIM24 expression in esophageal squamous cell carcinoma. Aging (Albany NY) 2016;8:2204-21. [PMID: 27689360 DOI: 10.18632/aging.101037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
6 Liu MC, Li XY, Zhan Y, Li J, Liu XM, Tan P, Wang XB, Liu SG. Polymorphism of ERCC1 rs3212986 in Chinese Han women with preeclampsia. Pregnancy Hypertens 2017;10:192-5. [PMID: 29153678 DOI: 10.1016/j.preghy.2017.08.007] [Reference Citation Analysis]
7 Findlay JM, Castro-Giner F, Makino S, Rayner E, Kartsonaki C, Cross W, Kovac M, Ulahannan D, Palles C, Gillies RS, MacGregor TP, Church D, Maynard ND, Buffa F, Cazier JB, Graham TA, Wang LM, Sharma RA, Middleton M, Tomlinson I. Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nat Commun 2016;7:11111. [PMID: 27045317 DOI: 10.1038/ncomms11111] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 8.7] [Reference Citation Analysis]
8 Gai J, Gao Z, Song L, Xu Y, Liu W, Zhao C. Contrast-enhanced computed tomography combined with Chitosan-Fe3O4 nanoparticles targeting fibroblast growth factor receptor and vascular endothelial growth factor receptor in the screening of early esophageal cancer. Exp Ther Med 2018;15:5344-52. [PMID: 29805549 DOI: 10.3892/etm.2018.6087] [Reference Citation Analysis]
9 Salnikova LE, Kolobkov DS. Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis. Pharmacogenomics J 2016;16:249-65. [PMID: 26122021 DOI: 10.1038/tpj.2015.46] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
10 Wang XS, Ding XZ, Li XC, He Y, Kong DJ, Zhang L, Hu XC, Yang JQ, Zhao MQ, Gao SG, Lin TY, Li Y. A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically. Nanomedicine 2018;14:2103-14. [PMID: 30047470 DOI: 10.1016/j.nano.2018.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Jiang D, Chen L, Huang J, Wang H, Song Q, Shi P, Wang H, Hou Y. Mouse double minute 2 amplification in oesophageal squamous cell carcinoma is associated with better outcome. Histopathology 2020;77:963-73. [PMID: 32652667 DOI: 10.1111/his.14208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Boldrin E, Malacrida S, Rumiato E, Battaglia G, Ruol A, Amadori A, Saggioro D. Association Between ERCC1 rs3212986 and ERCC2/XPD rs1799793 and OS in Patients With Advanced Esophageal Cancer. Front Oncol 2019;9:85. [PMID: 30847299 DOI: 10.3389/fonc.2019.00085] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
13 Fisher OM, Lord SJ, Falkenback D, Clemons NJ, Eslick GD, Lord RV. The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis. Gut 2017;66:399-410. [PMID: 26733670 DOI: 10.1136/gutjnl-2015-310888] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
14 Narumiya K, Bollschweiler E, Hölscher AH, Yamamoto M, Drebber U, Alakus H, Metzger R, Warnecke-Eberz U. Different response rates to chemotherapy between Japanese and German esophageal squamous cell carcinoma: patients may be influenced by ERCC1 or ABCB1. Future Oncol 2020;16:2075-87. [PMID: 32611208 DOI: 10.2217/fon-2020-0489] [Reference Citation Analysis]
15 Bollschweiler E, Plum P, Mönig SP, Hölscher AH. Current and future treatment options for esophageal cancer in the elderly. Expert Opinion on Pharmacotherapy 2017;18:1001-10. [DOI: 10.1080/14656566.2017.1334764] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 8.4] [Reference Citation Analysis]
16 Rumiato E, Boldrin E, Malacrida S, Battaglia G, Bocus P, Castoro C, Cagol M, Chiarion-Sileni V, Ruol A, Amadori A, Saggioro D. A germline predictive signature of response to platinum chemotherapy in esophageal cancer. Transl Res 2016;171:29-37.e1. [PMID: 26772957 DOI: 10.1016/j.trsl.2015.12.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
17 Goense L, Merrell KW, Arnett AL, Hallemeier CL, Meijer GJ, Ruurda JP, Hofstetter WL, van Hillegersberg R, Lin SH. Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer. The Annals of Thoracic Surgery 2018;106:1541-7. [DOI: 10.1016/j.athoracsur.2018.05.055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
18 Llop-Talaveron J, Badia-Tahull MB, Leiva-Badosa E. An inflammation-based prognostic score, the C-reactive protein/albumin ratio predicts the morbidity and mortality of patients on parenteral nutrition. Clin Nutr 2018;37:1575-83. [PMID: 28912009 DOI: 10.1016/j.clnu.2017.08.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
19 Papadopoulou E, Metaxa-Mariatou V, Tsaousis G, Tsoulos N, Tsirigoti A, Efstathiadou C, Apessos A, Agiannitopoulos K, Pepe G, Bourkoula E, Nasioulas G. Molecular predictive markers in tumors of the gastrointestinal tract. World J Gastrointest Oncol 2016; 8(11): 772-785 [PMID: 27895815 DOI: 10.4251/wjgo.v8.i11.772] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
20 Madi A, Fisher D, Maughan TS, Colley JP, Meade AM, Maynard J, Humphreys V, Wasan H, Adams RA, Idziaszczyk S, Harris R, Kaplan RS, Cheadle JP. Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. Eur J Cancer 2018;102:31-9. [PMID: 30114658 DOI: 10.1016/j.ejca.2018.07.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
21 Findlay JM, Bradley KM, Wang LM, Franklin JM, Teoh EJ, Gleeson FV, Maynard ND, Gillies RS, Middleton MR. Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized Therapy. J Nucl Med 2017;58:266-75. [PMID: 27635027 DOI: 10.2967/jnumed.116.176313] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
22 He J, Wang F, Zhu J, Zhang Z, Zou Y, Zhang R, Yang T, Xia H. The TP53 gene rs1042522 C>G polymorphism and neuroblastoma risk in Chinese children. Aging (Albany NY) 2017;9:852-9. [PMID: 28275206 DOI: 10.18632/aging.101196] [Cited by in Crossref: 27] [Cited by in F6Publishing: 49] [Article Influence: 5.4] [Reference Citation Analysis]
23 Lavery A, Turkington RC. Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer. Gastroenterol Rep (Oxf) 2020;8:411-24. [PMID: 33442473 DOI: 10.1093/gastro/goaa065] [Reference Citation Analysis]
24 Xu XL, Yu HQ, Hu W, Song Q, Mao WM. A Novel Inflammation-Based Prognostic Score, the C-Reactive Protein/Albumin Ratio Predicts the Prognosis of Patients with Operable Esophageal Squamous Cell Carcinoma. PLoS One. 2015;10:e0138657. [PMID: 26390126 DOI: 10.1371/journal.pone.0138657] [Cited by in Crossref: 68] [Cited by in F6Publishing: 80] [Article Influence: 9.7] [Reference Citation Analysis]
25 Wu YG, Li HF, Ren YJ, Zou DB, Zhang KN, Xiao X. The association of XRCC1 polymorphism with osteosarcoma risk, clinicopathologic features, and prognosis in a Chinese Han population. Cancer Manag Res 2018;10:4959-67. [PMID: 30464596 DOI: 10.2147/CMAR.S177452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
26 Pasternack H, Fassunke J, Plum PS, Chon SH, Hescheler DA, Gassa A, Merkelbach-Bruse S, Bruns CJ, Perner S, Hallek M, Büttner R, Bollschweiler E, Hölscher AH, Quaas A, Zander T, Weiss J, Alakus H. Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence. Sci Rep 2018;8:14941. [PMID: 30297788 DOI: 10.1038/s41598-018-33027-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
27 Nomizo T, Ozasa H, Tsuji T, Funazo T, Yasuda Y, Yoshida H, Yagi Y, Sakamori Y, Nagai H, Hirai T, Kim YH. Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients. Sci Rep. 2017;7:45124. [PMID: 28332580 DOI: 10.1038/srep45124] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
28 Coté D, Eustace A, Toomey S, Cremona M, Milewska M, Furney S, Carr A, Fay J, Kay E, Kennedy S, Crown J, Hennessy B, Madden S. Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH). PLoS One 2018;13:e0200996. [PMID: 30071039 DOI: 10.1371/journal.pone.0200996] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
29 Thomaschewski M, Hummel R, Petrova E, Knief J, Wellner UF, Keck T, Bausch D. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours. World J Gastroenterol 2018; 24(13): 1429-1439 [PMID: 29632424 DOI: 10.3748/wjg.v24.i13.1429] [Reference Citation Analysis]
30 Nieto T, Tomlinson CL, Dretzke J, Bayliss S, Dilworth M, Beggs AD, Tucker O. Epigenetic biomarkers in progression from non-dysplastic Barrett's oesophagus to oesophageal adenocarcinoma: a systematic review protocol. BMJ Open 2016;6:e013361. [PMID: 27927666 DOI: 10.1136/bmjopen-2016-013361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
31 Nieto T, Tomlinson CL, Dretzke J, Bayliss S, Price MJ, Dilworth M, Beggs AD, Tucker O. A systematic review of epigenetic biomarkers in progression from non-dysplastic Barrett's oesophagus to oesophageal adenocarcinoma. BMJ Open 2018;8:e020427. [PMID: 29961009 DOI: 10.1136/bmjopen-2017-020427] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
32 Yu Y, Yin YH, Min L, Zhu ST, Li P, Zhang ST. Challenge in the new era: Translational medicine in gastrointestinal endoscopy and early cancer. Chronic Dis Transl Med 2019;5:234-42. [PMID: 32055782 DOI: 10.1016/j.cdtm.2019.12.002] [Reference Citation Analysis]
33 Lee SY, Hong MJ, Jeon HS, Choi YY, Choi JE, Kang HG, Jung DK, Jin C, Do SK, Yoo SS, Seok Y, Lee EB, Shin KM, Jeong JY, Lee WK, Lee J, Cha SI, Kim CH, Kim YT, Jheon S, Park JY. Functional intronic ERCC1 polymorphism from regulomeDB can predict survival in lung cancer after surgery. Oncotarget 2015;6:24522-32. [PMID: 26056042 DOI: 10.18632/oncotarget.4083] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
34 Meulendijks D, Rozeman EA, Cats A, Sikorska K, Joerger M, Deenen MJ, Beijnen JH, Schellens JHM. Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. Pharmacogenomics J 2017;17:441-51. [DOI: 10.1038/tpj.2016.81] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
35 Findlay JM, Dickson E, Fiorani C, Bradley KM, Mukherjee S, Gillies RS, Maynard ND, Middleton MR. Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence. Eur Radiol 2019;29:6717-27. [PMID: 31278574 DOI: 10.1007/s00330-019-06310-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
36 Rumiato E, Boldrin E, Malacrida S, Battaglia G, Sileni VC, Ruol A, Amadori A, Saggioro D. Identification of host variants associated with overall survival of esophageal cancer patients receiving platinum-based therapy. Pharmacogenomics 2020;21:393-402. [PMID: 32285752 DOI: 10.2217/pgs-2019-0165] [Reference Citation Analysis]
37 Vrana D, Hlavac V, Brynychova V, Vaclavikova R, Neoral C, Vrba J, Aujesky R, Matzenauer M, Melichar B, Soucek P. ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer. Int J Mol Sci 2018;19:E868. [PMID: 29543757 DOI: 10.3390/ijms19030868] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
38 Hertz DL, Rae JM. Pharmacogenetic Predictors of Response. In: Stearns V, editor. Novel Biomarkers in the Continuum of Breast Cancer. Cham: Springer International Publishing; 2016. pp. 191-215. [DOI: 10.1007/978-3-319-22909-6_8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
39 Hamadou WS, Mani R, Bouali N, Besbes S, Bourdon V, El Abed R, Ben Youssef Y, Mari V, Gesta P, Dreyfus H, Bonadona V, Dugast C, Zattara H, Faivre L, Noguchi T, Khélif A, Sobol H, Soua Z. Mutational analysis of apoptotic genes in familial aggregation of hematological malignancies. Bull Cancer 2021:S0007-4551(21)00207-1. [PMID: 34140154 DOI: 10.1016/j.bulcan.2021.04.009] [Reference Citation Analysis]
40 Zhang P, Li Z, Wang D, Ma F, Zhang R, Liang W, Sun M, Fu Z, Sun X. 18F-fluorodeoxyglucose positron emission computed tomography for monitoring tumor response in esophageal carcinoma treated with concurrent chemoradiotherapy. Oncol Lett 2018;15:1845-52. [PMID: 29434881 DOI: 10.3892/ol.2017.7528] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Wang Q, Xu J, Xiong Z, Xu T, Liu J, Liu Y, Chen J, Shi J, Shou Y, Yue C, Liu D, Liang H, Yang H, Yang X, Zhang X. CENPA promotes clear cell renal cell carcinoma progression and metastasis via Wnt/β-catenin signaling pathway. J Transl Med 2021;19:417. [PMID: 34627268 DOI: 10.1186/s12967-021-03087-8] [Reference Citation Analysis]
42 Findlay JM, Bradley KM, Gillies RS, Maynard ND, Middleton MR. Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics. J Thorac Dis 2017;9:3551-2. [PMID: 29266129 DOI: 10.21037/jtd.2017.09.54] [Reference Citation Analysis]
43 Bollschweiler E, Hölscher AH, Herbold T, Metzger R, Alakus H, Schmidt H, Drebber U, Warnecke-Eberz U. Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study. Ann Surg 2016;264:839-46. [PMID: 27741011 DOI: 10.1097/SLA.0000000000001911] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]